Gene expression analysis of relapsing–remitting,primary progressive and secondary progressive multiple sclerosis

Abstract

Background:

Previous studies of multiple sclerosis (MS) have indicated differences in the pathogenesis in relapsing–remitting (RRMS), secondary progressive (SPMS) and primary progressive (PPMS) disease.

Objective:

We hypothesized that different MS subtypes would show differences in gene expression that could be traced to specific subsets of peripheral blood mononuclear cells (PBMCs).

Methods:

Gene expression in RRMS, SPMS, PPMS and healthy control (HC) PBMCs was analyzed on Affymetrix arrays. In addition, we studied gene expression in pools of purified PBMC subsets.

Results:

We found 380 genes that were differentially expressed in RRMS, PPMS, SPMS and HCs (false discovery rate < 5%). There were no major differences between the subtypes of MS. The genes showing most prominent expression changes in RRMS were associated with adaptive immune pathways, while genes in PPMS were associated with innate immune system pathways. SPMS patients shared pathways with RRMS and PPMS patients. Gene expression changes were most prominent in B cells, CD8+ T cells and monocytes.

Conclusion:

Differences in gene expression, which could be traced to B cells, CD8+ T cells and monocytes, were found between MS patients and HCs but only minor differences were observed between MS subgroups.

Keywords

Multiple sclerosis progressive multiple sclerosis microarray gene expression immunology pathway analysis

Get full access to this article

View all access options for this article.

References

Compston

Coles

. Multiple sclerosis. Lancet 2008; 372: 1502–1517.

Sawcer

Hellenthal

Pirinen

. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214–219.

Choi

Howell

Carassiti

. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012; 135: 2925–2937.

Frischer

Bramow

Dal-Bianco

. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175–1189.

Magliozzi

Howell

Reeves

. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010; 68: 477–493.

Achiron

Gurevich

Friedman

. Blood transcriptional signatures of multiple sclerosis: Unique gene expression of disease activity. Ann Neurol 2004; 55: 410–417.

Gandhi

McKay

Cox

. The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Hum Mol Genet 2010; 19: 2134–2143.

Lock

Hermans

Pedotti

. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8: 500–508.

Ramanathan

Weinstock-Guttman

Nguyen

. In vivo gene expression revealed by cDNA arrays: The pattern in relapsing–remitting multiple sclerosis patients compared with normal subjects. J Neuroimmunol 2001; 116: 213–219.

10.

Lublin

Reingold

. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907–911.

11.

Wei

Bumgarner

. Sample size for detecting differentially expressedgenes in microarray experiments. BMC Genomics. 2004;5:87

12.

Benjamini

Hochberg

. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Statist Soc B 1995; 57: 289–300.

13.

Roxburgh

Seaman

Masterman

. Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144–1151.

14.

Bomprezzi

Ringner

Kim

. Gene expression profile in multiple sclerosis patients and healthy controls: Identifying pathways relevant to disease. Hum Mol Genet 2003; 12: 2191–2199.

15.

Fossey

Vnencak-Jones

Olsen

. Identification of molecular biomarkers for multiple sclerosis. J Mol Diagn 2007; 9: 197–204.

16.

Kemppinen

Kaprio

Palotie

. Systematic review of genome-wide expression studies in multiple sclerosis. BMJ Open 2011; 1: e000053.

17.

Brynedal

Khademi

Wallstrom

. Gene expression profiling in multiple sclerosis: A disease of the central nervous system, but with relapses triggered in the periphery? Neurobiol Dis 2010; 37: 613–621.

18.

Gurevich

Tuller

Rubinstein

. Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells. BMC Med Genomics 2009; 2: 46.

19.

Ottoboni

Keenan

Tamayo

. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med 2012; 4: 153ra131.

20.

Satoh

Nakanishi

Koike

. T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients. J Neuroimmunol 2006; 174: 108–118.

21.

Satoh

Misawa

Tabunoki

. Molecular network analysis of T-cell transcriptome suggests aberrant regulation of gene expression by NF-kappaB as a biomarker for relapse of multiple sclerosis. Dis Markers 2008; 25: 27–35.

22.

Arthur

Armati

Bye

. Genes implicated in multiple sclerosis pathogenesis from consilience of genotyping and expression profiles in relapse and remission. BMC Med Genet 2008; 9: 17.

23.

Hesse

Krakauer

Lund

. Disease protection and interleukin-10 induction by endogenous interferon-beta in multiple sclerosis? Eur J Neurol 2011; 18: 266–272.

24.

van Baarsen

van der Pouw Kraan

Kragt

. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun 2006; 7: 522–531.

25.

Yamaguchi

Ruderman

Croze

. IFN-beta-regulated genes show abnormal expression in therapy-naive relapsing–remitting MS mononuclear cells: Gene expression analysis employing all reported protein-protein interactions. J Neuroimmunol 2008; 195: 116–120.

26.

Christensen

Börnsen

Ratzer

. Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. PLoS One 2013; 8: e57820.

27.

Friese

Fugger

. Pathogenic CD8(+) T cells in multiple sclerosis. Ann Neurol 2009; 66: 132–141.

28.

Hauser

Waubant

Arnold

. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med 2008; 358: 676–688.

29.

Hawker

O’Connor

Freedman

. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460–471.

30.

Kappos

Calabresi

. Ocrelizumab in relapsing–remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378: 1779–1787.

31.

Bar-Or

Fawaz

Fan

. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 2010; 67: 452–461.

32.

Weiner

. A shift from adaptive to innate immunity: A potential mechanism of disease progression in multiple sclerosis. J Neurol 2008; 255 (Suppl 1): 3–11.

33.

Iglesias

Camelo

Hwang

. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J Neuroimmunol 2004; 150: 163–177.

34.

Mayne

Moffatt

Kong

. CYFIP2 is highly abundant in CD4+ cells from multiple sclerosis patients and is involved in T cell adhesion. Eur J Immunol 2004; 34: 1217–1227.

35.

Riveros

Mellor

Gandhi

. A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis. PLoS One 2010; 5: e14176.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.62 MB

0.10 MB

0.12 MB

0.09 MB

0.02 MB